Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to tackle Hard-to-Treat myeloma

NCT ID NCT07084896

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, belantamab mafodotin and nirogacestat, in people with multiple myeloma that has returned or not responded to at least three prior treatments. The goal is to find a safe dose and see how well the combination shrinks tumors. About 106 adults are taking part in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
belantamab mafodotin and nirogacestat
What this could lead to
If it works, this combination could offer a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is an early-phase trial with only 106 participants, so results may not apply to everyone. Side effects like low blood counts and eye problems are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

  • 238995

    Atlanta, Georgia, 30322, United States

  • 239015

    Madison, Wisconsin, 53792, United States

  • 240593

    Boston, Massachusetts, 02215, United States

  • 251164

    Grand Rapids, Michigan, 49546, United States

  • GSK Investigational Site

    Fitzroy, Victoria, 3065, Australia

  • GSK Investigational Site

    Vancouver, British Columbia, V5Z1M9, Canada

  • GSK Investigational Site

    Halifax, Nova Scotia, B3H 1V7, Canada

  • GSK Investigational Site

    Lille, 59037, France

  • GSK Investigational Site

    Villejuif, 94805, France

  • GSK Investigational Site

    Frankfurt, 60590, Germany

  • GSK Investigational Site

    Kiel, 24105, Germany

  • GSK Investigational Site

    Leipzig, 04103, Germany

  • GSK Investigational Site

    Athens, 11528, Greece

  • GSK Investigational Site

    Utrecht, 3584 CX, Netherlands

  • GSK Investigational Site

    Oslo, 0450, Norway

  • GSK Investigational Site

    Katowice, 40-519, Poland

  • GSK Investigational Site

    Lodz, 93-513, Poland

  • GSK Investigational Site

    Lublin, 20-081, Poland

  • GSK Investigational Site

    Moscow, 125284, Russia

  • GSK Investigational Site

    Incheon, 21565, South Korea

  • GSK Investigational Site

    Seoul, 06351, South Korea

  • GSK Investigational Site

    Seoul, 06591, South Korea

  • GSK Investigational Site

    Ulsan, 44033, South Korea

  • GSK Investigational Site

    Badalona, 08916, Spain

  • GSK Investigational Site

    Madrid, 28041, Spain

  • GSK Investigational Site

    Madrid, 31008, Spain

  • GSK Investigational Site

    Pozuelo de AlarcOn Madr, 28223, Spain

  • GSK Investigational Site

    Falun, SE-791 82, Sweden

  • GSK Investigational Site

    Stockholm, SE-141 86, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.